Source-grounded facts extracted from Oncology Institute, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Oncology Institute, Inc. shareholders approved Approval, on a non-binding, advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company’s named executive officers (the “Say-on-Frequency Proposal”) at the 2026-06-17 meeting.
“The Say-on-Frequency Proposal was approved”
Oncology Institute, Inc. shareholders approved Approval, on a non-binding, advisory basis, of the Company’s named executive officers (the “Say-on-Pay Proposal”) at the 2026-06-17 meeting.
“The Say-on-Pay Proposal was approved.”
Oncology Institute, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accountants at the 2026-06-17 meeting.
“The ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved.”
Oncology Institute, Inc. shareholders approved Election of eight directors at the 2026-06-17 meeting.
“The Company’s stockholders elected eight directors to serve for the ensuing year and until their successors are elected and qualified, or until their earlier death, resignation or removal.”
Oncology Institute, Inc. reported three months ended March 31, 2026 results: revenue $147.4 million, net income $2.5 million, EPS $(0.02). Guidance reaffirmed.
“maintaining high-quality care. First Quarter 2026 Financial Highlights All comparisons are to the quarter ended March 31, 2025 unless otherwise noted • Consolidated revenue of $147.4 million increased 41.2% from $104.4 million • Gross profit of $23.3 million, increased 35.2% • Net loss of $2.5 million compared to net loss of $19.6 million • Basic and diluted (loss)”
Oncology Institute, Inc. reported fiscal year ended December 31, 2025 results: revenue $502.7 million, net income Net loss of $60.6 million, EPS $(0.54) basic and diluted loss per share.
“million as of December 31, 2025 Year Ended 2025 Financial Highlights All comparisons are to the year ended December 31, 2024 unless otherwise noted • Consolidated revenue of $502.7 million, increased 27.8% • Gross profit of $76.4 million, an increase of 41.6% • Net loss of $60.6 million compared to $64.7 million • Basic and diluted loss per share of $(0.54) and”
Oncology Institute, Inc. reported fourth quarter ended December 31, 2025 results: revenue $142.0 million, net income Net loss of $7.5 million, EPS $(0.06) basic and diluted loss per share.
“MA lives in South Florida Fourth Quarter 2025 Financial Highlights All comparisons are to the quarter ended December 31, 2024 unless otherwise noted • Consolidated revenue of $142.0 million, increased 41.6% • Gross profit of $22.7 million, an increase of 55.2% • Net loss of $7.5 million compared to $13.2 million • Basic and diluted loss per share of $(0.06) compared”
Jeremy Castle resigned as Chief Operating Officer at Oncology Institute, Inc..
“On May 2, 2025, Jeremy Castle provided notice of his resignation as Chief Operating Officer of The Oncology Institute, Inc. (the “Company”), effective as of May 30, 2025.”
Oncology Institute, Inc.: Increased the number of shares of Series A Convertible Preferred Stock from unspecified prior amount to 213,000 via an amendment to the Certificate of Designation, effective March 24, 2025, and also filed a Certificate of Correction to correct an administrative error (effective 2025-03-24).
“On March 24, 2025, the Company filed an amendment to Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock (the “ Certificate of Designation ” and such amendment, the “Amendment to Certificate of Designation ”) with the Secretary of State of the State of Delaware in connection with the Exchange , effective on March 24, 2025.”
Oncology Institute, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 19, 2024 (the “Second Nasdaq Bid Price Letter”), Nasdaq notified the Company that Nasdaq’s Staff has determined that the Company is eligible for an additional 180 calendar day period, or until June 16, 2025, to regain compliance (the “Second Compliance Period”). The determination is based on the Company’s meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market with the exception of the Minimum Bid Price Requirement, and the Company’s written notice of its intention to cure”
Maeve O'Meara resigned as Director at Oncology Institute, Inc..
“On November 8, 2024, Maeve O’Meara notified the Board of Directors of The Oncology Institute, Inc. (the “Company”) of her intention to resign as a director of the Company for personal reasons, effective as of January 1, 2025 (the “Effective Date”).”
Robert Carter was appointed as Chief Financial Officer at Oncology Institute, Inc..
“On September 20, 2024, the Company appointed Robert Carter to replace Mr. Shah as the Company’s Chief Financial Officer, with effect on October 14, 2024.”
Mihir Shah resigned as Chief Financial Officer at Oncology Institute, Inc..
“On September 19, 2024, Mihir Shah, the Chief Financial Officer, principal financial officer, and principal accounting officer of The Oncology Institute, Inc. (the “Company”), delivered a notice of resignation effective as of October 14, 2024.”
Oncology Institute, Inc. reported three months ended March 31, 2024 results: revenue $95 million, net income Net loss of $19.9 million, EPS $(0.22) and $(0.22). Guidance reaffirmed.
“Officer • Hired 7 new providers in the quarter and ended the quarter with 73 clinics and 126 employed providers First Quarter 2024 Financial Highlights • Consolidated revenue of $95 million, an increase of 24.2% from $76 million compared to the prior year quarter • Gross profit of $12 million, a decrease of 15.1% compared to the prior year quarter, and gross margin”
Oncology Institute, Inc. reported financial results for the three months and year ended December 31, 2023.
“On April 3, 2024, The Oncology Institute, Inc. (the "Company") issued a slide presentation which includes the Company's financial results for the three months and year ended December 31, 2023 and certain other financial information.”
Oncology Institute, Inc. reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $86 million, net income $18.8 million, EPS $(0.21).
“Officer. • Hired 7 new providers in the quarter and ended the year with 69 clinics and 119 employed providers. Fourth Quarter 2023 Financial Highlights • Consolidated revenue of $86 million, an increase of 20.1% compared to the prior year quarter • Gross profit of $14 million, a decrease of 8.0% compared to the prior year quarter • Net loss of $18.8 million compared”
Oncology Institute, Inc. reported three months ended September 30, 2023 results: revenue $82 million, net income Net loss of $17.4 million, EPS $(0.19). Guidance reaffirmed.
“new Chief Operating Officer • Signed full-risk capitated contract in South Florida, effective January 1, 2024 Third Quarter 2023 Financial Highlights • Consolidated revenue of $82 million, an increase of 26% compared to the prior year quarter • Gross profit of $16 million, an increase of 23% compared to the prior year quarter, and gross margin of 19.5%, a decrease”
Matthew Miller, MD departed as Chief Operations Officer at Oncology Institute, Inc..
“Dr. Miller’s separation from the Company was effective June 16, 2023, as previously disclosed in that certain Current Report on Form 8-K filed with the Securities and Exchange Commission on May 22, 2023.”
Jeremy N. Castle was appointed as Chief Operations Officer at Oncology Institute, Inc..
“On September 5, 2023, The Oncology Institute, Inc., a Delaware corporation (the “Company”), appointed Jeremy N. Castle to replace Matthew Miller, MD as the Company’s Chief Operations Officer.”
Ravi Sarin resigned as Director at Oncology Institute, Inc..
“On August 31, 2023, Ravi Sarin, a member of the Board of Directors (the “Board”) of The Oncology Institute, Inc. (the “Company”), resigned effective immediately as a director of the Board, including any positions held as a member of any committee of the Board.”
Oncology Institute, Inc. reported financial results for the six months ended June 30, 2023.
“On August 10, 2023, The Oncology Institute, Inc. (the "Company") issued a slide presentation which includes the Company's financial results for the three months and six months ended June 30, 2023 and certain other financial information.”
Oncology Institute, Inc. reported financial results for the three months ended June 30, 2023.
“On August 10, 2023, The Oncology Institute, Inc. (the "Company") issued a slide presentation which includes the Company's financial results for the three months and six months ended June 30, 2023 and certain other financial information.”
Oncology Institute, Inc. updated its three months ended June 30, 2023 guidance (reaffirmed).
“On August 8, 2023, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2023 and certain other financial information.”
Oncology Institute, Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-15 meeting.
“Proposal 2: Ratification of the Appointment of Independent Registered Public Accountants The ratification of the appointment of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, the stockholders voted as follows: Votes For Votes Against Abstentions Broker Non-Votes 64,306,320 444,591 245,712 —”
Oncology Institute, Inc. shareholders approved Election of nine directors at the 2023-06-15 meeting.
“Proposal 1: Election of Directors All nine nominated directors were elected to hold office until the Company's 2024 annual meeting of stockholders. The stockholders voted as follows: Nominee Votes For Votes Against Votes Withheld Broker Non-Votes Brad Hively 53,352,627 — 961,581 10,682,415 Richard Barasch 53,577,014 — 737,194 10,682,415 Karen Johnson 53,236,553 — 1,077,655 10,682,415 Mohit Kaushal 41,300,185 — 13,014,023 10,682,415 Anne McGeorge 40,469,060 — 13,845,148 10,682,415 Maeve O’Meara 52,748,849 — 1,565,359 10,682,415 Ravi Sarin 40,412,516 — 13,901,692 10,682,415 Gabriel Ling 53,854,419 — 459,789 10,682,415 Mark Pacala 54,230,930 — 83,278 10,682,415”
Daniel Virnich was appointed as Chief Executive Officer at Oncology Institute, Inc..
“the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer effective as of June 30, 2023”
Brad Hively changed role as Vice Chair of the Board at Oncology Institute, Inc..
“Brad Hively will transition from his role as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”) to Vice Chair of the Board of Directors of the Company.”
Daniel Virnich was appointed as Chief Executive Officer at Oncology Institute, Inc..
“Effective as of June 30, 2023, the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer”
Brad Hively was appointed as Vice Chair of the Board at Oncology Institute, Inc..
“Additionally, the Board appointed Mr. Hively to serve as Vice Chair of the Board at the Effective Time”
Brad Hively resigned as Chief Executive Officer at Oncology Institute, Inc..
“On June 11, 2023, Brad Hively provided notice of his resignation as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”), effective June 30, 2023 (the “Effective Date”).”
Matthew Miller was terminated as Chief Operating Officer at Oncology Institute, Inc..
“In connection with the Company’s termination of its Chief Operating Officer, Matthew Miller, M.D., effective June 16, 2023, on May 18, 2023, the Company notified Dr. Miller of his termination from his position as the Chief Operating Officer of the Company.”
Oncology Institute, Inc. reported three months ended March 31, 2023 results: revenue $76 million, net income Net loss of $30.0 million, EPS $(0.33). Guidance reaffirmed.
“savings • Patient visits up 17% compared to Q1 2022 • Oral drugs dispensed increased 34% compared to Q1 2022 First Quarter 2023 Financial Highlights • Consolidated revenue of $76 million, an increase of 38.1% from $55 million compared to the prior year quarter • Gross profit of $14 million, an increase of 14.4% compared to the prior year quarter, and gross margin”
Oncology Institute, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(2)).
“April 25, 2023, The Oncology Institute, Inc. (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5450(a)(2), because the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Notice”). The Notice has no immediate effect on the listing or trading of the Company’s common stock or warrants on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until Octobe”
Oncology Institute, Inc. reported fourth quarter ended December 31, 2022 results: revenue $71 million, net income Net loss of $11.0 million, EPS $(0.12) and $(0.16).
“Fourth Quarter 2022 Financial Highlights • Consolidated revenue of $71 million, an increase of 36.6% from $52 million compared to the prior year quarter • Gross profit of $16 million, an increase of 87.6% compared to the prior year quarter • Net loss of $11.0 million compared to net loss of $10.2 million for the prior year quarter • Basic and diluted earnings per share of $(0.12) and $(0.16), respectively, compared to $(0.13) for the prior year quarter”
Oncology Institute, Inc. reported financial results for the year ended December 31, 2022.
“The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023”
Oncology Institute, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $71 million, net income $9.5 million, EPS $(0.11) and $(0.15).
“• Consolidated revenue of $71 million, an increase of 36.6% from $52 million compared to the prior year quarter • Gross profit of $16 million, an increase of 87.6% compared to the prior year quarter • Net loss of $9.5 million compared to net loss of $10.2 million for the prior year quarter • Basic and diluted earnings per share of $(0.11) and $(0.15), respectively, compared to $(0.13) for the prior year quarter”
Diona Simoneit resigned as Chief Accounting Officer at Oncology Institute, Inc..
“On November 27, 2022, Diona Simoneit, Chief Accounting Officer and principal accounting officer of The Oncology Institute, Inc. (the “Company”), notified the Company of her intent to resign from her position, effective December 9, 2022.”
Oncology Institute, Inc. reported financial results for three and nine months ended September 30, 2022.
“Item 2.02. Results of Operations and Financial Condition On November 15, 2022, The Oncology Institute, Inc. (the "Company") issued a slide presentation which includes the Company's financial results for the three and nine months ended September 30, 2022 and certain other financial information. A copy of the presentation is furnished hereto as Exhibit 99.1, which are incorporated by reference herein.”
Oncology Institute, Inc. reported three months ended September 30, 2022 results: revenue $65 million, net income Net loss of $2.7 million, EPS $(0.03). Guidance raised.
“Reger in newly created Chief Information Officer role and Cristina Green as Vice President of Clinical Research Third Quarter 2022 Financial Highlights • Consolidated revenue of $65 million, an increase of 24.3% from $52 million for the prior year quarter • Gross profit of $13 million, an increase of 13.8% compared to the prior year quarter • Net loss of $2.7”
Gabriel Ling was appointed as Director at Oncology Institute, Inc..
“the Board appointed Mr. Mark Pacala and Mr. Gabriel Ling to the Board, effective immediately”
Mark Pacala was appointed as Director at Oncology Institute, Inc..
“the Board appointed Mr. Mark Pacala and Mr. Gabriel Ling to the Board, effective immediately”
Scott Dalgleish departed as Chief Financial Officer at Oncology Institute, Inc..
“Mr. Dalgleish’s last date of employment with the Company was April 29, 2022.”
Mihir Shah was appointed as Chief Financial Officer at Oncology Institute, Inc..
“Effective as of April 4, 2022, the Company appointed Mihir Shah, to replace Mr. Dalgleish as the Company’s Chief Financial Officer”
Scott Dalgleish departed as Chief Financial Officer at Oncology Institute, Inc..
“Mr. Dalgleish will cease serving as the Company’s Chief Financial Officer effective April 4, 2022.”
Dr. Matthew Miller changed role as Chief Operating Officer at Oncology Institute, Inc..
“On March 2, 2022, the Board of Directors of the Company promoted Dr. Matthew Miller to succeed Dr. Virnich as Chief Operating Officer, effective as of March 15, 2022.”
Dr. Daniel Virnich changed role as President at Oncology Institute, Inc..
“On March 2, 2022, the Board of Directors of The Oncology Institute, Inc. (the "Company") promoted Dr. Daniel Virnich to serve as President of the Company, effective as of March 15, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.